

## HA-Ahx-Ahx-Ub-VS (human sequence, synthetic)

UbiQ code : UbiQ-187 Batch # : B01112016-001


Amount : 50 ug, lyophilized powder Purity :  $\geq$ 95% by RP-HPLC

Mol. Weight: 9.93 kDa

Storage: upon arrival, powder at -20°C; buffered solution at -80°C. Please avoid multiple freeze/thaw cycles.

## **Productsheet**

**Background.** UbiQ-187 is an activity-based probe for deubiquitinating enzymes (DUBs). It contains a C-terminal electrophilic vinyl sulfone (VS) group and is labeled on the N-terminus with the HA peptide sequence (YPYDVPDYA) derived from the influenza hemagglutinin protein and allows for the sensitive identification or purification of DUBs by anti-HA antibodies and/or anti-HA-agarose. The HA tag is separated from the N-terminus by two 6-aminohexanoic acid (Ahx) linkers for efficient recognition of the tag. UbiQ-187 can be used for activity profiling experiments and determining DUB inhibitor specificity.



**Figure 1**. A: sequence; to eliminate Met1 oxidation, Met1 is replaced by norleucine, a well validated methionine mimic. B: LC-MS analysis. Mobile phase A= 1% CH<sub>3</sub>CN, 0.1% formic acid in water and B= 1% water and 0.1% formic acid in CH<sub>3</sub>CN. XBridge BEH300 C18  $5\mu$ m 4.6x100mm; flow rate = 0.8 mL/min, runtime = 10 min, column T = 40°C. Gradient: 30-60% B over 6.5 min.

## important: sample preparation

- dissolve the powder in as little DMSO as possible (e.g. 20 40 mg/mL)
- add this DMSO stock slowly to milliQ (please note the order of addition)
- buffer the aq. solution as desired
- for detailed experimental conditions please see open-access reference 1

Please note we and others have observed the appearance of smearing during SDS-PAGE analysis of (di)Ub conjugates. This can be caused by (heat-induced) aggregation (Morimoto et al. Sci Rep 2018, 8, article 2711). If possible, avoid heating the samples in Laemmli sample buffer for SDS-PAGE analysis and/or add 4M urea to the SDS-PAGE samples.

**Literature.** (1) de Jong et al. *ChemBioChem* **2012**, *13*, 2251. (2) Borodovsky et al. *EMBO J* **2001**, *20*, 5187. (3) Xu et al. *RSC Adv* **2016**, *6*, 47926.